Transport - Dubai RTA Introduces Five-Star Ranking System for Taxi Companie… Weather - Light Rain Expected in Some Areas on November 17 as Dubai Tempe… Update - Zayed National Museum and Bahrain Launch Six-Week Archaeologica…

Send an Inquiry

Fill in the details below and our team will get back to you.

Business 1 min read 140 views

GLP-1 Stocks Surge 130% in Five Years, Outpacing Global Markets

GLP-1 weight-loss and diabetes drug producers have delivered remarkable gains over the past five years, with shares of leading companies rising 130% — far outpacing broader global markets, according to an analysis by eToro.

The analysis compared two baskets of pharmaceutical firms — one comprising GLP-1 drug producers such as Novo Nordisk, Eli Lilly, Sanofi, Teva, and Hikma, and another featuring non-GLP-1 peers like Novartis, Johnson & Johnson, GlaxoSmithKline, AbbVie, and Bayer.

Josh Gilbert, Market Analyst at eToro, stated:

“Over five years, the GLP-1 basket has surged 130%, compared with just 42% for non-GLP-1 firms. That performance also outpaced the S&P 500 (+98%), the EuroStoxx 50 (+73%), and the FTSE 100 (+59%).”

Despite recent market headwinds, GLP-1 manufacturers continue to outperform traditional pharmaceutical players. Over the past year, the GLP-1 basket fell 12% amid a global correction, while non-GLP-1 pharma stocks gained 10%. Novo Nordisk shares dropped 50% over the same period, yet the company remains a key market leader.

Eli Lilly Emerges as Top Performer
Over the five-year period, Eli Lilly’s stock climbed an impressive 486%, followed by Teva at 116% and Novo Nordisk at 76%, despite a pullback in 2025. On the other hand, Hikma saw a 28% decline. Among non-GLP-1 firms, AbbVie led with a 168% rise, while Bayer dropped nearly 40%.

A Booming Market for Weight-Loss Treatments
The global market for GLP-1 weight-loss drugs is projected to reach USD 130 billion by 2030, requiring nearly 50% annual growth. However, recent corrections have tempered investor expectations after rapid valuation increases and profit warnings from major manufacturers such as Novo Nordisk, which recently announced 9,000 job cuts.

Novo Nordisk has long been the leader in this space, revolutionizing diabetes and weight management with its insulin and GLP-1 products. However, increasing demand has intensified competition, particularly from Eli Lilly, whose drug Zepbound has shown strong weight-loss results.

Middle East Impact and Growing Demand
The GLP-1 boom extends beyond global markets. In the UAE, where over one in five adults live with diabetes, rising adoption of GLP-1 treatments is reshaping healthcare supply chains and influencing lifestyle habits. Some Dubai restaurants have even introduced smaller portion menus catering to individuals using appetite-suppressing drugs.

While the sector faces short-term corrections, experts say the long-term growth potential remains vast.
Gilbert added that, “Despite a reality check, GLP-1s remain one of the most exciting opportunities in healthcare. Demand continues to grow rapidly, especially in the Middle East, with companies driving one of the biggest healthcare shifts in decades.”

GLP-1 stockseToro analysisNovo NordiskEli Lillyweight-loss drugsdiabetes treatmentUAE healthcarepharmaceutical marketglobal marketshealthcare innovation

Related News

More on Business

View all

Comments (0)

Join the conversation

No comments yet. Be the first to share your thoughts!

More News

See all
Real Estate

UAE office rents rise as limited supply keeps market favourable for landlords

The UAE's office market continued to favour landlords in the third quarter of 2026 as limited new supply and sustained demand pushed vacancy rates lower and supported rental growth. Meanwhile, the retail sector remained resilient, with visits to community and regional malls holding up despite...

Nov 17, 2026 · 3 min
Technology

Sharjah launches Agentic AI Challenge to advance digital transformation

The Sharjah Digital Department (SDD) has launched the Sharjah Agentic AI Challenge to accelerate the adoption of agentic artificial intelligence across government operations and promote human-centred digital transformation. The challenge will take place from December 8 to 10, 2026, in line with...

Nov 17, 2026 · 2 min
Healthcare

Hamdan Foundation hosts family innovation event in Dubai during UAE Innovates 2026

The Hamdan Bin Rashid Al Maktoum Foundation for Medical and Educational Sciences organised an innovation event in Dubai under the theme 'A Family that Innovates, Generations that Inspire', as part of UAE Innovates 2026 and the UAE's Year of Family. Held on November 16 at the Foundation's...

Nov 17, 2026 · 2 min
Business

DMW and DataFlow Group launch digital recruitment platform in Dubai

The Philippines' Department of Migrant Workers (DMW) and DataFlow Group have signed an agreement to launch a pilot of the Digital Recruitment Employment Accreditation Management Platform (DREAM) in Dubai, introducing a fully digital accreditation process for employers and recruitment agencies...

Nov 17, 2026 · 2 min
Trusted by

Our Associates

Brands and organisations that work with Day of Dubai.